B+
Bull case
25%
Probability
Target price
$66.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
TWST
Twist BioscienceFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$54.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
This is a T+1 earnings follow-up with high headline buzz but only partial post-print digestion. Primary-source evidence is strong and mixed: the company delivered a revenue beat, raised full-year revenue guidance, and reiterated breakeven goals, yet the stock fell from the $60.40 May 1 anchor to $56.73 on May 4, 2026, implying the market weighed the EPS/loss profile, settlement charge, and remaining execution risk more heavily than the top-line beat. Reliable analyst target or rating revisions were not yet available at this stage, which keeps the memo in monitoring mode rather than supporting a stronger directional upgrade.
RankAlpha Sentiment Codex - 2026-05-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-12catalystPost-earnings digestion after revenue beat but EPS/litigation noiseMedium impact
Fiscal 2Q26 revenue rose 19% to $110.7M, gross margin reached 51.6%, and full-year revenue guidance was raised to $442M-$447M, but GAAP net loss widened to $44.0M with a $7.2M quarterly litigation-settlement charge tied to an approximately $17.1M settlement in principle; shares traded at $56.73 on May 4, 2026 versus the $60.40 pre-print anchor, showing that investors focused on earnings quality and cash burn as much as the top-line beat [#8-K-2026-05-04].
2026-05-21eventMay 21 investor day could tighten the H2 growth and margin narrativeMedium impact
Twist scheduled an Investor Day for May 21, 2026, where management plans to discuss strategic initiatives, growth opportunities, and the roadmap ahead; this is the nearest company-set event that could either validate the raised outlook and H2 NGS acceleration plan or expose how much of the margin and breakeven path still depends on execution [#IR-2026-04-21].
2026-09-30catalystExecution toward Q4 FY26 adjusted EBITDA breakeven remains the core rerating hookHigh impact
Management reiterated a target to reach adjusted EBITDA breakeven in fiscal 4Q26, keep full-year gross margin above 52%, and drive H2 sequential growth with NGS returning to 20% growth by 4Q; if Twist delivers on that path while sustaining double-digit DSPS and NGS growth, the market could revisit a higher multiple, but slippage would likely reinforce the current cautious stance [#8-K-2026-05-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology